Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 63 articles: HTML format Text format

Single Articles

January 2012
1. BRUNDAGE M , Gropp M, Mefti F, Mann K, et al
   Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.
   Ann Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. BONDONG S , Kiefel H, Hielscher T, Zeimet AG, et al
   Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation.
   Ann Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
3. BELL-MCGUINN K , Konner J, Tew W, Spriggs DR, et al
   New drugs for ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii77-viii82.
   PubMed     Text format     Related articles   
   
   
   
   
4. SESSA C
   Update on PARP1 inhibitors in ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii72-viii76.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. MARKMAN M
   The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
   Ann Oncol. 2011;22 Suppl 8:viii69-viii71.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. BURGER RA
   Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii65-viii68.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. URBAN N
   Designing early detection programs for ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii6-viii18.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. BAST RC JR
   Molecular approaches to personalizing management of ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii5-viii15.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. EISENHAUER EA
   Optimal assessment of response in ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii49-viii51.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. RUSTIN GJ
    Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.
    Ann Oncol. 2011;22 Suppl 8:viii45-viii48.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. PIGNATA S , Cannella L, Leopardo D, Bruni GS, et al
    Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.
    Ann Oncol. 2011;22 Suppl 8:viii40-viii44.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. VAN DER BURG ME , Boere IA, Berns PM
    Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra.
    Ann Oncol. 2011;22 Suppl 8:viii33-viii39.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. KATSUMATA N
    Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
    Ann Oncol. 2011;22 Suppl 8:viii29-viii32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. KANG S , Park SY
    To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer.
    Ann Oncol. 2011;22 Suppl 8:viii23-viii28.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. HACKER NF
    Quality control in ovarian cancer surgery.
    Ann Oncol. 2011;22 Suppl 8:viii19-viii22.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
16. ROCHON J , du Bois A
    Clinical research in epithelial ovarian cancer and patients' outcome.
    Ann Oncol. 2011;22 Suppl 7:vii16-vii19.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. BRAGA S
    Why do our patients get chemotherapy until the end of life?
    Ann Oncol. 2011;22:2345-8.
    PubMed     Text format     Related articles   
    
    
    
    
18. NAPPA U , Lindqvist O, Rasmussen BH, Axelsson B, et al
    Palliative chemotherapy during the last month of life.
    Ann Oncol. 2011;22:2375-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
19. GLADIEFF L , Ferrero A, De Rauglaudre G, Brown C, et al
    Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
20. SEHOULI J , Alfaro V, Gonzalez-Martin A
    Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
21. LORTHOLARY A , Largillier R, Weber B, Gladieff L, et al
    Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINE
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
22. LAVIE O , Narod S, Lejbkowicz F, Dishon S, et al
    Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Ann Oncol. 2011;22:964-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
23. KURTZ JE , Kaminsky MC, Floquet A, Veillard AS, et al
    Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. RUSTIN G , Reed N, Jayson GC, Ledermann JA, et al
    A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. WEBERPALS JI , Tu D, Squire JA, Amin MS, et al
    Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
26. CHAN KK , Yao TJ, Jones B, Zhao JF, et al
    The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. TORIOLA AT , Grankvist K, Agborsangaya CB, Lukanova A, et al
    Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
28. ZWEIFEL M , Jayson GC, Reed NS, Osborne R, et al
    Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. DORN J , Magdolen V, Gkazepis A, Gerte T, et al
    Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. JUNG YW , Seong SJ, Kim JW
    Should diagnostic laparoscopy be conducted before hormonal treatment in early-stage endometrial cancer?
    Ann Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
31. VENCKEN PM , Kriege M, Hoogwerf D, Beugelink S, et al
    Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. PARADISO A , Muggia F
    Hereditary breast and ovarian cancer: risks and challenges. 10-12 September 2009: Bari, Italy. Introduction.
    Ann Oncol. 2011;22 Suppl 1:i5-6.
    PubMed     Text format     Related articles   
    
    
    
    
33. 
    Hereditary breast and ovarian cancer: risks and challenges. Proceedings of a meeting. September 10-12, 2009. Bari, Italy.
    Ann Oncol. 2011;22 Suppl 1:i5-68.
    PubMed     Text format     Related articles   
    
    
    
    
34. MUGGIA F , Safra T, Dubeau L
    BRCA genes: lessons learned from experimental and clinical cancer.
    Ann Oncol. 2011;22 Suppl 1:i7-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. MUGGIA F , Smaldone V, Paradiso A
    Conclusions: fruits of the convergence of laboratory, clinic and public.
    Ann Oncol. 2011;22 Suppl 1:i67-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. CALVERT H , Azzariti A
    The clinical development of inhibitors of poly(ADP-ribose) polymerase.
    Ann Oncol. 2011;22 Suppl 1:i53-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. RADICE P , De Summa S, Caleca L, Tommasi S, et al
    Unclassified variants in BRCA genes: guidelines for interpretation.
    Ann Oncol. 2011;22 Suppl 1:i18-23.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. MILNE RL , Antoniou AC
    Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
    Ann Oncol. 2011;22 Suppl 1:i11-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
39. NAGLE CM , Kolahdooz F, Ibiebele TI, Olsen CM, et al
    Carbohydrate intake, glycemic load, glycemic index, and risk of ovarian cancer.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
40. DOBRZYCKA B , Terlikowski SJ, Kinalski M, Kowalczuk O, et al
    Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. GALLAGHER DJ , Konner JA, Bell-McGuinn KM, Bhatia J, et al
    Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. SESSA C , D'Incalci M
    Trabectedin in ovarian cancer: could we expect more?
    Ann Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    October 2010
43. DORN J , Harbeck N, Kates R, Gkazepis A, et al
    Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. LEDERMANN JA , Kristeleit RS
    Optimal treatment for relapsing ovarian cancer.
    Ann Oncol. 2010;21 Suppl 7:vii218-vii222.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. BOOKMAN MA
    The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer.
    Ann Oncol. 2010;21 Suppl 7:vii211-vii217.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. MACKAY J , Szecsei CM
    Genetic counselling for hereditary predisposition to ovarian and breast cancer.
    Ann Oncol. 2010;21 Suppl 7:vii334-vii338.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
47. MINIG L , Franchi D, Boveri S, Casadio C, et al
    Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. KANAGAVEL D , Pokataev IA, Fedyanin MY, Tryakin AA, et al
    A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
    Ann Oncol. 2010;21:1779-85.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
49. UZAN C , Kane A, Rey A, Gouy S, et al
    How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage II-III serous borderline tumours of the ovary.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. BIAGI JJ , Oza AM, Chalchal HI, Grimshaw R, et al
    A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. SWENERTON KD , Santos JL, Gilks CB, Kobel M, et al
    Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
52. KAYE SB , Colombo N, Monk BJ, Tjulandin S, et al
    Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. POVEDA A , Vergote I, Tjulandin S, Kong B, et al
    Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
54. ALEXANDRE J , Ray-Coquard I, Selle F, Floquet A, et al
    Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. SEHOULI J , Pietzner K, Harter P, Munstedt K, et al
    Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. REED N , Millan D, Verheijen R, Castiglione M, et al
    Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2010;21 Suppl 5:v31-6.
    PubMed     Text format     Related articles   
    
    
    
    
57. COLOMBO N , Peiretti M, Parma G, Lapresa M, et al
    Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2010;21 Suppl 5:v23-30.
    PubMed     Text format     Related articles   
    
    
    
    March 2010
58. CHUANG E , Wiener N, Christos P, Kessler R, et al
    Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. MITCHELL CL , O'Connor JP, Jackson A, Parker GJ, et al
    Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
60. ALETTI GD , Nordquist D, Hartmann L, Gallenberg M, et al
    From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2009
61. PECORELLI S , Ray-Coquard I, Tredan O, Colombo N, et al
    Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2009
62. UZAN C , Kane A, Rey A, Gouy S, et al
    Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2009
63. AEBI S , Castiglione M
    Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    Ann Oncol. 2009;20 Suppl 4:21-3.
    PubMed     Text format     Related articles   
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: